See more : China Wafer Level CSP Co., Ltd. (603005.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sky Gold Limited (SKYGOLD.NS) Income Statement Analysis – Financial Results
- Sichuan Hongda Co.,Ltd (600331.SS) Income Statement Analysis – Financial Results
- Liquid Avatar Technologies Inc. (LQID.CN) Income Statement Analysis – Financial Results
- Northern Star Resources Limited (NST.AX) Income Statement Analysis – Financial Results
- Atlas Salt Inc. (REMRF) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Metric | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|
Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
EPS | -0.18 | -0.20 | 0.00 | 0.00 |
EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma further validates lead candidate MSP-1014 as a next generation psilocybin analog through drug discrimination assay
Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay
Maxim Group hikes price target for Mindset Pharma to US$1.50 after the company develops a specialized preclinical rodent model
Maxim Group hikes price target for Mindset Pharma to US$1.50 after the company develops a specialized pre-clinical rodent model
Mindset Pharma selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for MSP-1014
Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate
Mindset Pharma develops specialized preclinical rodent trained studies with its drugs to differentiate between psychedelic and non-psychedelic effects
Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs to Differentiate Between Their Psychedelic and Non-Psychedelic Effects
Mindset Pharma reports encouraging safety data concerning its Family 4 group of DMT analogs
Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved Safety Profile in Preclinical Results
Source: https://incomestatements.info
Category: Stock Reports